Viral Hepatitis and Hepatocellular Carcinoma

Archives of Medical Research

Volumn 38, Issue 6, 2007, Pages 612-620

  Marrero, Carlos Romero ^a   Marrero, Jorge A ^b  

^a UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Diagnosis; Hepatitis B; Hepatitis C; Hepatocellular carcinoma

Indexed keywords

ADEFOVIR; ALCOHOL; ALPHA FETOPROTEIN; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B VACCINE; INTERFERON; LAMIVUDINE;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SURVIVAL; DIABETES MELLITUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; OBESITY; REVIEW; RISK FACTOR; SIDE EFFECT; SMOKING; TOBACCO; ULTRASOUND; VIRUS HEPATITIS; VIRUS RESISTANCE;

CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; RISK FACTORS; SEER PROGRAM;

EID: 34347207184     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2006.09.004     Document Type: Review

References (71)

1. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2 (2001) 533-543
2. El-Serag H.B. Global epidemiology of hepatocellular carcinoma. Clin Liver Dis 5 (2001) 87-107
3. Bosch F.X., Ribes J., Diaz M., and Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127 (2004) S5-S16
4. El-Serag H.B. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127 (2004) S7-S34
5. McGlynn K.A., Tsao L., Hsing A.W., Devessa S.S., and Fraumeni J.F. International trends and patterns of primary liver cancer. Int J Cancer 94 (2001) 290-296
6. Davila J.A., McGlynn K.A., and El-Serag H.B. The changing incidence of hepatocellular carcinoma in the United States. Clin Gastroenterol Hepatol 4 (2006) 104-408
7. El-Serag H.B., Mason A.C., and Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 33 (2001) 62-65
8. El-Serag H.B. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 5 (2001) 87-107
9. Beasley R.P. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer 61 (1988) 1942-1956
10. Beasley R.P., Hwang L.Y., Lin C.C., and Chien C.S. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22,707 men in Taiwan. Lancet 2 (1981) 1129-1133
11. Fattovich G., Stroffolini T., Zagni I., and Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127 (2004) S35-S50
12. Bosch F.X., Ribes J., and Borras J. Epidemiology of primary liver cancer. Semin Liv Dis 19 (1999) 271-285
13. El-Serag H.B., Davila J.A., Petersen N.J., and McGlynn K.A. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139 (2003) 117-123
14. Hassan M.M., Frome A., Patt Y.Z., and El-Serag. Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. J Clin Gastroenterol 35 (2002) 266-269
15. Kulkarni K., Barcak E., El-Serag H.B., and Goodgame R. The impact of immigration on the increasing incidence of hepatocellular carcinoma. Aliment Pharmacol Ther 20 (2004) 445-502
16. El Serag H.B., and Mason A.C. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 160 (2000) 3227-3230
17. Davila J., Morgan R., Shaib Y., McGlynn K., and El-Serag H.B. Hepatitis C infection and the rising incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 127 (2004) 1372-1380
18. Tanaka Y., Kurbanov F., Mano S., Orito E., Vargas V., Esteban J.I., et al. Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology 130 (2006) 703-714
19. Marrero J.A., and Pelletier S. Diagnosis and treatment of hepatocellular carcinoma. Clin Liv Dis (2006) (in press)
20. Niederau C., Lange C., Heintges T., Erhardt A., Buschkamp M., Hurter D., et al. Prognosis of hepatitis C: results of a large, prospective cohort study. Hepatology 28 (1998) 1687-1695
21. Fattovich G., Giustina G., Degos F., Tremolada F., Diodati G., Almasio P., et al. Morbidity and mortality in compensated cirrhosis C: a retrospective follow-up study of 384. Gastroenterology 112 (1997) 463-472
22. Fattovich G., Giustina G., Schalm S.W., Hadziyannis S., Sanchez-Tapias J., Almasio P., et al. Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B. Hepatology 21 (1995) 77-82
23. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
24. Kao J.H., Chen P.J., Lai M.Y., and Chen D.S. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 118 (2000) 554-559
25. Donato F., Boffetta P., and Puoti M. A metaanalysis of epidemiological studies on the combined effects of hepatitis B and C virus in causing hepatocellular carcinoma. Int J Cancer 75 (1998 Jan 30) 347-354
26. Donato F., Tagger A., Gelatti U., Parrinello G., Bofetta P., Albertini A., et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and viral hepatitis infection in men and women. Am J Epidemiol 155 (2002) 323-331
27. Chen Z.M., Liu B.Q., Boreham J., Wu Y.P., Chen J.S., Peto R., et al. Smoking and liver cancer in China: case-control comparison of 36,000 liver cancer deaths vs. 17,000 cirrhosis deaths. Int J Cancer 107 (2003) 106-112
28. Calle E.E., Rodriguez C., Walker-Thurmond K., and Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348 (2003) 1625
29. Donato F., Gelatti U., Limina R.M., and Fattovich G. Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiological evidence. Oncogene 25 (2006) 3756-3770
30. Kensler T.W., Egner P.A., Wang J.B., Zhu Y.R., Zhang B.C., Lu P., et al. Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas. Gastroenterology 127 (2004) S310-S318
31. Wang L.Y., Hatch M., Chen C.J., Levin B., You S.L., Lu S.N., et al. Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int J Cancer 67 (1996) 620-625
32. Ikeda K., Arase Y., Saitoh S., Kobayashi M., Someya T., Hosaka T., et al. Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts. J Hepatology 44 (2006) 1089-1097
33. Velazquez R.F., Rodriguez M., Navascues C.A., Linares A., Perez R., Sotorrios N.G., et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 37 (2003) 520-527
34. Nair S., Mason A., Eason J., Loss G., and Perrillo R.P. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis. Hepatology 36 (2002) 150-155
35. N'kontchou G., Paries J., Htar M.T., Ganne-Carrie N., Costentin L., Grando-Lemaire V., et al. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. Clin Gastroenterol Hepatol 4 (2006) 1062-1068
36. Kuper H., Tzonou A., Kaklamani E., Hsieh C.C., Lagiou P., Adami H.O., et al. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 85 (2000) 498-502
37. Franceschi S., Montella M., Polesel J., La Vecchia C., Crispo A., Dal Maso L., et al. Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy. Cancer Epidemiol Biomarkers Prev 15 (2006) 683-689
38. El-Serag H.B., Tran T., and Everhart J. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126 (2004) 460-468
39. Marrero J.A., Banegura A., Fu S., Cojeevaram H., Su G., Fontana R., and Lok A. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 42 (2005) 218-224
40. Cole P., and Morrison A.S. Basic issues in population screening for cancer. J Natl Cancer Inst 64 (1980) 1263-1272
41. Meissner H.I., Smith R.A., Rimer B.K., Wilson K.M., Rakowski W., Vernon S.W., et al. Promoting cancer screening: learning from experience. Cancer 101 (2004) 1107-1117
42. Bruix J., and Sherman M. Management of hepatocellular carcinoma: AASLD Practice Guideline. Hepatology 42 (2005) 1208-1236
43. Sarasin F.P., Giostra E., and Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 101 (1996) 422-434
44. Arguedas M.R., Chen V.K., Eloubeidi M.A., and Fallon M.B. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol (2003) 98679-98690
45. Marrero J.A. Screening tests for hepatocellular carcinoma. Clin Liver Dis 9 (2005) 235-251
46. Trevisani F., D'Intino P.E., Morselli-Labate A.M., Mazzella G., Accogli E., Caraceni P., et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 34 (2001) 570-575
47. Pateron D., Ganne N., Trinchet J.C., Aurousseau M.H., Mal F., Meicler C., et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 20 (1994) 65-71
48. Zoli M., Magalotti D., Bianchi G., Gueli C., Marchesini G., and Pisi E. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer 78 (1996) 977-985
49. Izuno K., Fujiyama S., Yamasaki K., Sato M., and Sato T. Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-gamma-carboxy prothrombin and alpha-fetoprotein: a prospective study. Hepatogastroenterology 42 (1995) 387-393
50. Sherman M. Screening for hepatocellular carcinoma. Baillieres Best Pract Res Clin Gastroenterol 13 (1999) 623-635
51. Chen T.H., Chen C.J., Yen M.F., Lu S.N., Sun C.A., Huang G.T., et al. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int J Cancer 98 (2002) 257-261
52. Larcos G., Sorokopud H., Berry G., and Farrell G.C. Sonographic screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis: an evaluation. AJR Am J Roentgenol 171 (1998) 433-435
53. Zhang B.H., Yang B.H., and Tang Z.Y. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130 (2004) 417-422
54. Burrel M., Llovet J.M., Ayuso C., Iglesias C., Sala M., Miquel R., et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 38 (2003) 1034-1042
55. Krinsky G.A., Lee V.S., Thiese N.D., Wienreb J.C., Rofsky N.M., Diflo T., et al. Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: prospective diagnosis with MR imaging and explant correlation. Radiology 219 (2001) 445-454
56. Bolondi L., Gaiani S., Celli N., Golfieri R., Grigioni W.F., Leoni S., et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 42 (2005) 27-34
57. Chang C.J., Chen M.S., Lai H.M., Hsu T.C., Wu M.S., Kong D.C., et al. Taiwan Childhood Hepatoma Study Group. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 336 (1997) 1855-1859
58. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., Huang G.T., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
59. McMahon B.J., Holck P., Bulkow L., and Snowball M.M. Serologic and clinical outcomes 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med 135 (2001) 759-768
60. Camma M., Giunta P., and Andreone A. Craxi. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 34 (2001) 593-602
61. Lin I.S., Sheen R.N., Chien C.M., Chu Y.F., and Liaw Y.F. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 29 (1999) 971-975
62. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., Tanwandee T., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521
63. Nishiguchi S., Shiomi S., Nakatani T., Takeda K., Fukuda A., Tamori D., et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 357 (2001) 196-197
64. Valla D.C., Chevallier M., Marcellin P., Payen J.L., Trepo C., Fonck M., et al. Treatment of hepatitis C virus related cirrhosis a randomized controlled trial of interferon alfa 2b versus no treatment. Hepatology 29 (1999) 1870-1875
65. Bernardinello E., Cavalletto L., Chemello L., Mezzocolli C., Donada C., Benvegnu L., et al. Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. Hepatogastroenterology 46 (1999) 3216-3222
66. Baffis V.I., Shrier A.H., Sherker, and Szilagvi A. Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection. Ann Intern Med 131 (1999) 696-701
67. Camma C.M., Giunta P., Andreone, and Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis an evidence-based approach. J Hepatol 34 (2001) 593-602
68. Papatheodoridis G.V., Papadimitropoulos V.C., and Hadziyannis S.J. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis a meta-analysis. Aliment Pharmacol Ther 15 (2001) 689-698
69. Yoshida Y., Shiratori M., Moriyama Y., Arakawa T., Sata I de M., Inoue O., et al., IHIT Study Group. Interferon therapy reduces the risk for hepatocellular carcinoma national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 131 (1999) 174-181
70. Gelatti U., Covolo L., Franceschini M., Pirali F., Tagger A., Ribero M.L., et al. Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: a case-control study. J Hepatol 42 (2005) 528-534
71. Inoue M., Yoshimi I., Sobue T., Tsugane S., and JPHC Study Group. . Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst 97 (2005) 293-300